Luis E. Raez, MD

Luis E. Raez, MD, discusses when minimal residual disease testing can be performed as an option for patients with lung cancer.

Luis E. Raez, MD, discusses the current liquid biopsy options for patients with lung cancer through assessing circulating tumor DNA.

In this companion article, Dr Luis Raez provides insights into effective management patients with extensive-stage small cell lung cancer who develop chemotherapy-induced myelosuppression.

Luis E. Raez, MD, FACP, FCCP, immediate past president of Florida Society of Clinical Oncology, evaluates the role of biomarker testing for lung cancer and other disease types.

Dr Luis Raez shares his perspectives on ways to manage thrombocytopenia in patients receiving chemotherapy for ES-SCLC treatment.

Luis E. Raez, MD, discusses the treatment of TRK fusion-positive lung cancers in the past and the present.

Luis Raez, MD, reviews the case of a 67-year-old man with metastatic non-small cell NTRK gene fusion lung cancer.

Luis E. Raez, MD, discusses targeted therapies for patients with lung cancer who have genetic alterations.